The Medicare risk contracting business has always been dogged by accusations that it cherry-picks enrollees. In its earliest form, the claim was that the plans sought the healthiest beneficiaries as enrollees. Now that CMS has begun risk adjusting payments for the latest iteration of Medicare risk contracting, Medicare Advantage, the plans are charged with seeking less healthy enrollees, for whom they get higher payments and with doing extensive assessments to multiply the diagnoses which lead to the increased reimbursement. An article in the Journal of Health Economics examines the reality of these practices. (JHE Article) The authors used medical claims from two Medicare Advantage plans, one with a contracted provider design and one in an integrated delivery system/health plan model. The authors found that over 48 combinations of medical conditions, the two types of plans have highly correlated margins, suggesting that the model of plan makes little difference. For both plans, margins varied very widely across the 48 combinations. And they find that for conditions which generally are treated by primary care physicians and are amenable to care management, the average cost of treatment is lower for Medicare Advantage than in fee-for-service Medicare, but the same is not true for conditions which are more commonly treated by specialists or are acute conditions for which care management often offers little benefit. The authors find no evidence to support the hypothesis that Medicare Advantage plans recruit patients with the higher-margin combinations of conditions.
Medicare Advantage Plans and Enrollee Selection
By Kevin RocheJanuary 22, 2014Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 25, 2023
Coronamonomania Lives Forever, Part 201
Tired of March Madness? A boringly refreshing dip into some CV-19 research summaries is recommended.
March 24, 2023
The CDC Is a Font of Methodological and Statistical Error
Several times in the last three years I and others have pointed out serious flaws…
March 24, 2023
A Couple of Health Care Notes
A couple of pieces of health care research focus on high health care spending and…